Canurta Therapeutics is pleased to share that CEO Akeem Gardner participated in the ACT (Accelerating Clinical Trials) Canada Consortium on October 9-10, 2024. This event brought together leaders in the biotechnology industry, researchers, and key stakeholders to advance and accelerate high-impact clinical trials aimed at improving health outcomes.
During the biotechnology pitch session, Akeem presented a 3-minute pitch on Canurta’s lead asset, CNR-401, a botanical therapeutic developed to target ALS (Amyotrophic Lateral Sclerosis).
Gardner’s presentation outlined Canurta’s unique approach to ALS treatment using cannflavins, compounds known for their potent anti-inflammatory properties. This presentation showcased Canurta’s continued efforts to advance CNR-401 into human trials and engage with key partners to accelerate clinical development.
Watch the full presentation below for more details on Canurta’s progress and the potential impact of CNR-401.
Comments